Intratumoral IL-12 delivery via mesenchymal stem cells combined with PD-1 blockade leads to long-term antitumor immunity in a mouse glioblastoma model

Background: Although PD -1 blockade is effective for treating several types of cancer, the efficacy of this agent in glioblastoma is largely limited. To overcome non -responders and the immunosuppressive tumor microenvironment, combinational immunotherapeutic strategies with anti -PD -1 need to be considered. Here, we developed IL12 -secreting mesenchymal stem cells (MSC_IL-12) with glioblastoma tropism and evaluated the therapeutic effects of anti -PD -1, MSC_IL-12, and their combination against glioblastoma. Methods: Therapeutic responses were evaluated using an immunocompetent mouse orthotopic model. Tumorinfiltrating lymphocytes (TILs) were analyzed using immunofluorescent imaging. Single -cell transcriptome was obtained from mouse brains after treatments. Results: Anti -PD -1 and MSC_IL-12 showed complete tumor remission in 25.0% (4/16) and 23.1% (3/13) of glioblastoma-implanted mice, respectively, and their combination yielded synergistic antitumor efficacy indicated by 50.0% (6/12) of complete tumor remission. Analyses of TILs revealed that anti -PD -1 increased CD8 + T cells, while MSC_IL-12 led to infiltration of CD4 + T cells and NK cells. Both therapies reduced frequencies of Tregs. All these aspects observed in each monotherapy group were superimposed in the combination group. Notably, no tumor growth was observed upon rechallenge in cured mice, indicating long-term immunity against glioblastoma provoked by the therapies. Single -cell RNA-seq data confirmed these results and revealed that the combined treatment led to immune -favorable tumor microenvironment -CD4 + , CD8 + T cells, effector memory T cells, and activated microglia were increased, whereas exhausted T cells, Tregs, and M2 polarized microglia were reduced. Conclusion: Anti -PD -1 and MSC_IL-12 monotherapies show long-term therapeutic responses, and their combination further enhances antitumor efficacy against glioblastoma via inducing immune -favorable tumor microenvironment.